Cargando…
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
OBJECTIVE: Antimicrotubular agents are among the most commonly used classes of chemotherapeutic agents, but the risk of cardiovascular adverse events (CVAEs) remains unclear. Our objective was to study the CVAEs associated with antimicrotubular agents. METHODS: The Food and Drug Administration’s Adv...
Autores principales: | Batra, Akshee, Patel, Brijesh, Addison, Daniel, Baldassarre, Lauren A, Desai, Nihar, Weintraub, Neal, Deswal, Anita, Hussain, Zeeshan, Brown, Sherry-Ann, Ganatra, Sarju, Agarwala, Vivek, Parikh, Purvish M, Fradley, Michael, Ghosh, Arjun, Guha, Avirup |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710909/ https://www.ncbi.nlm.nih.gov/pubmed/34952868 http://dx.doi.org/10.1136/openhrt-2021-001849 |
Ejemplares similares
-
Vinca Alkaloids
por: Moudi, Maryam, et al.
Publicado: (2013) -
Length of stay and cost of care associated with admissions for atrial fibrillation among patients with cancer
por: Guha, Avirup, et al.
Publicado: (2022) -
In vitro antagonism between cisplatin and vinca alkaloids.
por: Lee, K., et al.
Publicado: (1989) -
New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies
por: Orosz, F, et al.
Publicado: (1999) -
Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
por: Lee, Chun-Ting, et al.
Publicado: (2015)